Stivarga 40mg comprimidos,3 x 28(Regorafenib)

Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Stivarga
Manufacturer	Bayer Vital GmbH GB Pharma
Prescription required	Yes

Description

Stivarga 40mg comprimidos,3 x 28(Regorafenib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Regorafenib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Bayer Vital GmbH GB Pharma. Therapeutic category: Medicine Library > Oncology Medicines > Hepatocellular Carcinoma. Pack information: 40 / 84. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

STIVARGA is a kinase inhibitor indicated for the treatment of adult patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

How to Use

Use Regorafenib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: Regorafenib. Pack size: 40 / 84. Pack unit: box. Manufacturer: Bayer Vital GmbH GB Pharma. Origin country: Spain. Source category: Medicine Library > Oncology Medicines > Hepatocellular Carcinoma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.